Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
doi: 10.3389/fmed.2022.875430 Summary Keywords glucagon-like peptide-1 receptor agonist (GLP-1RA), incretin based therapy, glucose-depent insulinotropic peptide (GIP), dual agonists, tirzepatide, type 2 diabetes Citation Gallwitz B (2022) Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
Order online, walk into any of 4,500+ LabCorp or Quest draw sites, and get results in 1-2 business days
-1775582746855.png&w=3840&q=75)
Due to tirzepatide's long half-life (approximately five days) and delayed peak concentration (8-72 hours after injection), symptoms typically reflect steady-state effects rather than immediate post-injection peaks
These side effects are generally mild to moderate and usually go away within a few weeks
A previously discussed search approach was used to extract 12,700 research articles
